221 related articles for article (PubMed ID: 3074229)
1. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
Mathé G; Reizenstein P; Eriguchi M
Suppl J Med Oncol Tumor Pharmacother; 1988; 1():75-92. PubMed ID: 3074229
[No Abstract] [Full Text] [Related]
2. Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.
Mathé G; Reizenstein P; Eriguchi M
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):75-92. PubMed ID: 2663216
[TBL] [Abstract][Full Text] [Related]
3. [Biotherapy of solid tumors].
Moiseenko VM
Vopr Onkol; 1998; 44(1):120-5. PubMed ID: 9578746
[No Abstract] [Full Text] [Related]
4. The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells.
Mertelsmann R
Eur Cytokine Netw; 1995; 6(2):79-82. PubMed ID: 7578991
[No Abstract] [Full Text] [Related]
5. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
6. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson HC; Klein HG
Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
[No Abstract] [Full Text] [Related]
7. [Oncology update '89. I].
Pfreundschuh M
Med Klin (Munich); 1989 Nov; 84(11):542-7. PubMed ID: 2687674
[No Abstract] [Full Text] [Related]
8. [Chemo- and immunotherapy of colorectal cancer].
Klein HO
Internist (Berl); 1991 Jun; 32(6):348-53. PubMed ID: 1880013
[No Abstract] [Full Text] [Related]
9. [Reflexions on early chemotherapy and complementary immunotherapy for treatment of solid tumors].
Amiel JL; Droz JP; Pilleron JP
Nouv Presse Med; 1977 Apr; 6(18):1559-62. PubMed ID: 405655
[No Abstract] [Full Text] [Related]
10. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
[TBL] [Abstract][Full Text] [Related]
11. Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes.
Chareyron S; Alamir M
J Theor Biol; 2009 Jun; 258(3):444-54. PubMed ID: 18655792
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy drug interactions with biological agents.
Sznol M; Longo DL
Semin Oncol; 1993 Feb; 20(1):80-93. PubMed ID: 8475413
[No Abstract] [Full Text] [Related]
13. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
14. New survival curve model for comparison of adjuvant therapy of malignant diseases.
Eriguchi M; Mathé G
Biomed Pharmacother; 1986; 40(4):143-7. PubMed ID: 3790708
[TBL] [Abstract][Full Text] [Related]
15. Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited.
Gabrilovich DI
Lancet Oncol; 2007 Jan; 8(1):2-3. PubMed ID: 17196504
[No Abstract] [Full Text] [Related]
16. Brain tumors.
Obbens EA; Schneider AG; Shapiro WR
Cancer Chemother Biol Response Modif; 1996; 16():625-43. PubMed ID: 8639405
[No Abstract] [Full Text] [Related]
17. Clinical trials of the treatment of minimal residual tumours.
Mathé G; Reizenstein P; Eriguchi M
Drugs Exp Clin Res; 1986; 12(1-3):83-98. PubMed ID: 3525078
[TBL] [Abstract][Full Text] [Related]
18. International workshop on surgical adjuvant antineoplastic chemotherapy in solid tumors. Conclusions and recommendations of the workshop. New aspects of surgical adjuvant chemotherapy.
Eckhardt S; Marx G
Arch Geschwulstforsch; 1978; 48(7):612-5. PubMed ID: 736741
[No Abstract] [Full Text] [Related]
19. Brain tumors.
Obbens EA; Shapiro WR
Cancer Chemother Biol Response Modif; 1993; 14():606-27. PubMed ID: 8312122
[No Abstract] [Full Text] [Related]
20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
